Effects of the selective sodium-glucose cotransporter 2 inhibitor empagliflozin on vascular function and central hemodynamics in patients with type 2 diabetes mellitus

Circulation

Volumn 136, Issue 12, 2017, Pages 1167-1169

  Striepe, Kristina ^a   Jumar, Agnes ^a   Ott, Christian ^a   Karg, Marina V ^a   Schneider, Markus P ^a   Kannenkeril, Dennis ^a   Schmieder, Roland E ^a  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Central systolic pressure; Empagliflozin; Pulse wave analysis; SGLT 2 inhibitor; Type 2 diabetes mellitus

Indexed keywords

EMPAGLIFLOZIN; GLUCOSE; HEMOGLOBIN A1C; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ADULT; ANTIDIABETIC ACTIVITY; ARTERIAL PRESSURE; ARTERIAL STIFFNESS; AUGMENTATION INDEX; BLOOD PRESSURE MONITORING; BLOOD VESSEL FUNCTION; BODY WEIGHT; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIABETIC PATIENT; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; HEART RATE; HEMODYNAMICS; HUMAN; LETTER; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; PROSPECTIVE STUDY; PULSE PRESSURE; PULSE WAVE; RADIAL ARTERY; RANDOMIZED CONTROLLED TRIAL; SYSTOLIC BLOOD PRESSURE; ADMINISTRATION AND DOSAGE; ADOLESCENT; AGED; CARDIOVASCULAR DISEASE; CONVALESCENCE; DRUG ADMINISTRATION; GERMANY; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; TIME FACTOR; TREATMENT OUTCOME; YOUNG ADULT;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; CROSS-OVER STUDIES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; FEMALE; GERMANY; GLUCOSIDES; HEMODYNAMICS; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECOVERY OF FUNCTION; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS; TIME FACTORS; TREATMENT OUTCOME; VASCULAR STIFFNESS; YOUNG ADULT;

EID: 85030993345     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.117.029529     Document Type: Letter

References (5)

1. Roden M, Merker L, Christiansen AV, Roux F, Salsali A, Kim G, Stella P, Woerle HJ, Broedl UC; EMPA-REG EXTEND™ MONO investigators. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial. Cardiovasc Diabetol. 2015;14:154. doi: 10.1186/s12933-015-0314-0.
2. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, Mattheus M, Devins T, Johansen OE, Woerle HJ, Broedl UC, Inzucchi SE; EMPA-REG OUTCOME Investigators. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373:2117-2128. doi: 10.1056/NEJMoa1504720.
3. Mancia G, Fagard R, Narkiewicz K, Redón J, Zanchetti A, Böhm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013;31:1281-1357. doi: 10.1097/01. hjh.0000431740.32696.cc.
4. Weber T, Wassertheurer S, Rammer M, Haiden A, Hametner B, Eber B. Wave reflections, assessed with a novel method for pulse wave separation, are associated with end-organ damage and clinical outcomes. Hypertension. 2012;60:534-541. doi: 10.1161/HYPERTENSIONAHA.112.194571.
5. Ott C, Jumar A, Striepe K, Friedrich S, Karg MV, Bramlage P, Schmieder RE. A randomised study of the impact of the SGLT2 inhibitor dapagliflozin on microvascular and macrovascular circulation. Cardiovasc Diabetol. 2017;16:26. doi: 10.1186/s12933- 017-0510-1.